Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William James Enright
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- -0.39
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -5.82
Financials
Revenue
$0.00-100.0%Net Income
$-10.58MEBITDA
$-8.93MFree Cash Flow
$-8.09MEPS (diluted)
$-0.26Shares Outstanding (diluted)
40.85M+422.6%Operating Expenses
$11.02MCash & Debt
$59.30MRevenue by Segment (annual)
$14.97MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-66.58M | $-1.64 |
| 2024 | $14.97M | $-61.07M | $-1.55 |
| 2023 | $802.0K | $-73.35M | $-1.91 |
| 2022 | $44.70M | $5.34M | $0.14 |
| 2021 | $268.0K | $-50.87M | $-1.37 |
| 2020 | $4.82M | $-17.71M | $-2.24 |
| 2019 | $6.85M | $-20.73M | $-436.87 |
Valuation
BRNShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Negative
…ymbol “CLYD” following completion of the proposed combination with Clywedog GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. (“Clywedog”) in an all-stock transaction.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.25 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.26 vs $-0.28beat
- Thu, Apr 30$-0.14 vs $-0.36beat
- Fri, Mar 13$-0.27 vs $-0.40beat
- Fri, Nov 7$-0.36 vs $-0.45beat
- Thu, Aug 7$-0.52 vs $-0.29miss
- Wed, May 7$-0.49 vs $-0.34miss
Estimates and results for BRNS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BRNS officers and directors.
No open-market trades in the recent filings. All 26 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
26 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.